Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Soligenix, Inc. (SNGX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.8980+0.0281 (+3.23%)
At close: 1:00PM EST
0.8700 -0.03 (-3.12%)
After hours: 04:52PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close0.8699
Open0.8601
Bid0.8700 x 1400
Ask0.9200 x 800
Day's Range0.8600 - 0.9318
52 Week Range0.8300 - 2.8000
Volume268,212
Avg. Volume1,740,915
Market Cap38.5M
Beta (5Y Monthly)1.14
PE Ratio (TTM)N/A
EPS (TTM)-0.3630
Earnings DateNov 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.88
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for SNGX

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Soligenix, Inc.
    Analyst Report: Emergent BioSolutions IncEmergent BioSolutions makes vaccines and other products intended to protect civilian and military populations from emerging infectious diseases and chemical, biological or nuclear attacks. The company generates its revenue from product sales of its smallpox vaccine (ACAM2000), its anthrax vaccines (BioThrax and AV7909), and its Narcan nasal spray (a treatment for opioid overdoses), as well as from contract development and manufacturing services and contracts and grants. The USG is the company's primary customer, and provides it with significant product development funding. EBS shares are a component of the S&P 400 Index. The company has approximately 2,200 employees.
    Rating
    Fair Value
    Economic Moat
    3 months agoArgus Research
View more
  • Zacks Small Cap Research

    SNGX: Durable Immunity for RiVax® Vaccine…

    By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update RiVax® Demonstrates Durable Immunity in Mouse Model On November 4, 2021, Soligenix, Inc. (NASDAQ:SNGX) announced the publication of preclinical studies for RiVax®, the company’s heat stable ricin toxin vaccine) that showed durable protection for at least 12 months following immunization ( Novak et al., 2021 ).

  • PR Newswire

    Soligenix Announces Recent Accomplishments And Third Quarter 2021 Financial Results

    Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended September 30, 2021.

  • PR Newswire

    Soligenix Granted Pediatric Investigational Plan Waiver for HyBryte™ in CTCL in the United Kingdom

    Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has been granted a Pediatric Investigation Plan (PIP) product-specific waiver from the Medicines and Healthcare products Regulatory Agency (MHRA) for HyBryte™ (SGX301 or synthetic hypericin), which has successfully concluded a Phase 3 pivotal clinical study for the

Advertisement
Advertisement